Advisory Services Network LLC Has $550,000 Position in Iqvia Holdings Inc (IQV)

Advisory Services Network LLC increased its position in Iqvia Holdings Inc (NYSE:IQV) by 17.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,238 shares of the medical research company’s stock after acquiring an additional 632 shares during the period. Advisory Services Network LLC’s holdings in Iqvia were worth $550,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC increased its holdings in shares of Iqvia by 19.4% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock worth $293,000 after acquiring an additional 476 shares during the period. IFM Investors Pty Ltd increased its holdings in shares of Iqvia by 5.4% in the 3rd quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 478 shares during the period. State Treasurer State of Michigan increased its holdings in shares of Iqvia by 1.0% in the 3rd quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock worth $6,266,000 after acquiring an additional 500 shares during the period. Gateway Investment Advisers LLC increased its holdings in shares of Iqvia by 9.1% in the 3rd quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock worth $878,000 after acquiring an additional 563 shares during the period. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Iqvia by 6.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 9,500 shares of the medical research company’s stock worth $948,000 after acquiring an additional 600 shares during the period. 91.36% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director John G. Danhakl sold 221,900 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $126.63, for a total transaction of $28,099,197.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin C. Knightly sold 9,216 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $126.46, for a total transaction of $1,165,455.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 601,586 shares of company stock valued at $75,510,422. Insiders own 6.00% of the company’s stock.

Shares of IQV opened at $124.17 on Friday. The stock has a market capitalization of $24.76 billion, a P/E ratio of 28.48, a P/E/G ratio of 1.76 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09. Iqvia Holdings Inc has a 52-week low of $91.57 and a 52-week high of $135.48.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.03. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The company had revenue of $2.59 billion during the quarter, compared to analyst estimates of $2.58 billion. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the stock. Barclays reiterated an “overweight” rating and issued a $130.00 target price (up previously from $120.00) on shares of Iqvia in a research report on Wednesday, July 25th. Stifel Nicolaus increased their target price on shares of Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 25th. Piper Jaffray Companies increased their target price on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a research report on Tuesday, October 23rd. Wells Fargo & Co increased their target price on shares of Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a research report on Monday, August 13th. Finally, Mizuho set a $120.00 target price on shares of Iqvia and gave the company a “hold” rating in a research report on Monday, August 6th. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $131.67.

TRADEMARK VIOLATION NOTICE: This report was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.wkrb13.com/2018/11/10/advisory-services-network-llc-has-550000-position-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Conference Calls

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply